Navigation Links
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
Date:12/13/2012

INDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will stop one of three Phase 3 rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy. The decision followed a planned interim futility analysis of the FLEX-M study investigating tabalumab, also known as LY2127399, for the treatment of patients with moderate-to-severe RA who had an inadequate response to methotrexate therapy. The decision was not based on safety concerns, and patients currently enrolled in other tabalumab RA studies will continue treatment.

The FLEX-M study was designed to support registration of tabalumab as a potential treatment for RA, including an assessment of its effect on structural progression. Lilly continues to evaluate tabalumab in two other Phase 3 RA registration studies as well as an open-label extension study and several other smaller studies. Lilly is suspending enrollment of new patients in the RA program until additional analysis from other ongoing RA studies is completed in early 2013. These other studies are in different patient populations.

Phase 3 studies for systemic lupus erythematosus are ongoing and will continue to enroll new patients. Currently, there is no evidence to suggest that efficacy results from the FLEX-M study in RA are indicative of potential efficacy in the lupus population. Lilly remains committed to the ongoing Phase 3 lupus program.

"The results of this study were unexpected given the data generated in earlier Phase II clinical studies of tabalumab," said Eiry Roberts, M.D., vice president of autoimmune product development at Lilly. "We remain committed to patients with rheumatoid arthritis and lupus and will move rapidly to evaluate the impact of these data on the overall tabalumab clinical development program. Beyond tabalumab,
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Provides Update on Next Steps for Solanezumab
2. Lilly to Expand Indianapolis Insulin Manufacturing Operations
3. Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
4. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly Announces Results From Lung Cancer Study
7. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
8. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
9. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
10. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
11. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015  Immune ... KRS Global Biotechnology, Inc. for the compounding, packaging and distributing ... shipment in the United States . ... Facility capable of compounding naltrexone tablets in various strengths for ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located ... the number one best large hotel for families in the ... their annual Travelers’ Choice Awards. , TripAdvisor represents the ... home to millions of unbiased and honest traveler reviews. The ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... 15 HLTH Corporation (Nasdaq: HLTH ) and its ... ), today announced that they will release their respective financial results ... pm (ET) on Tuesday, May 5, 2009. The Companies will host ... discuss those results. Investors can access the call via webcast ...
... a relationship of hepatitis C (HCV) infection with type ... unclear. , A research article to be published on ... Gastroenterology addresses this question. The research team led ... of the People,s Liberation Army 161 Hospital in Wuhan ...
... pick the tunes, study suggests , , WEDNESDAY, April 15 (HealthDay ... to plug in that iPod or pop in a CD ... reduced their heart rates, breathing rate and blood pressure just ... previous studies found. , The report, published in the latest ...
... 15 Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), ... of novel antibiotics for the treatment of antibiotic-resistant infections, ... in China. The State Intellectual Property Office of ... Number ZL 2004 8 0021883.9 to Rib-X. This ...
... Further Reduces 2009 Operating Expenses to Address Continued ... Results on Tuesday, May 5 WESTFORD, Mass., ... (Nasdaq: CYNO ), a leading ... light-based aesthetic treatment systems, today announced preliminary, unaudited ...
... Efficacy than Levitra for Patients with Hypertension Priced at ... 50 Percent Patient Share in the U.S., According to ... Decision Resources, one of the world,s leading research ... that although surveyed primary care physicians (PCPs) are generally ...
Cached Medicine News:Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Do patients at risk for B-cell malignancy need antiviral treatment? 2Health News:Soothing Songs Please the Heart 2Health News:Rib-X Granted Key Antibiotic Patent in China 2Health News:Cynosure Announces Preliminary Financial Results for the First Quarter of 2009 2Health News:Cynosure Announces Preliminary Financial Results for the First Quarter of 2009 3Health News:Cynosure Announces Preliminary Financial Results for the First Quarter of 2009 4Health News:For Erectile Dysfunction, Physicians Indicate That Opportunity Exists for Emerging Therapies with Improved Efficacy in Difficult-to-Treat Patient Subpopulations 2Health News:For Erectile Dysfunction, Physicians Indicate That Opportunity Exists for Emerging Therapies with Improved Efficacy in Difficult-to-Treat Patient Subpopulations 3
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
... Designed for precise punching of ... is designed for use with disposable ... block aids in centration of the ... the block is held centrally under ...
Broad Tip and Ultra-Micro Needle Tip, sterile, 10 per Box, 10 Boxes per Case...
Medicine Products: